Novartis adds another Cosentyx approval with FDA nod

The FDA on 21 January gave its blessing to Novartis to market Cosentyx (secukinumab) as a treatment for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

The FDA on 21 January gave its blessing to Novartis to market Cosentyx (secukinumab) as a treatment for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Cosentyx, a first-in-class, fully human, monoclonal antibody (mAb), selectively binds to the proinflammatory cytokine interleukin-17A (IL-17A) and inhibits its interaction...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category